Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-09-10
Mancini Anthony Files Revolution Medicines (RVMD) Form 4 - September 10, 2026
Mancini Anthony traded 24.8K RVMD shares worth $3.5M in this Form 4 filing, reported to the SEC on 2026-09-10.
- Insider
- Mancini Anthony
- Issuer
- Revolution Medicines, Inc. RVMD · NASDAQ
- Filed
- Period
- 2026-09-10
- Accession
- 0002124509-26-000004
- Source
- Official filing on sec.gov ↗
Transactions (7)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Mancini Anthony | 2026-09-10 | Buy | 9.4K | $33.62 | $314.8K | Direct |
| Mancini Anthony | 2026-09-10 | Sell | 6.0K | $203.28 | $1.2M | Direct |
| Mancini Anthony | 2026-09-10 | Sell | 5.5K | $204.14 | $1.1M | Direct |
| Mancini Anthony | 2026-09-10 | Sell | 2.4K | $205.05 | $496.2K | Direct |
| Mancini Anthony | 2026-09-10 | Sell | 1.2K | $206.10 | $243.0K | Direct |
| Mancini Anthony | 2026-09-10 | Sell | 300 | $207.17 | $62.2K | Direct |
| Net change | −6.1K | −$2.8M | ||||
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.
Track RVMD insider activity
Get alerted when Revolution Medicines, Inc. executives buy or sell their shares.